ArticleJournal of global infectious diseases2010
Human immunodeficiency virus and leishmaniasis.
Article in Journal of global infectious diseases, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The diagnostic accuracy of serologic and molecular methods for detecting visceral leishmaniasis in HIV infected patients: meta-analysis.PLoS neglected tropical diseases · 2012Pooled it
- Antigen Detection in Urine for Noninvasive Diagnosis and Treatment Monitoring of Visceral Leishmaniasis in Human Immunodeficiency Virus Coinfected Patients: An Exploratory Analysis from Ethiopia.The American journal of tropical medicine and hygiene · 2018Trial
- CoReGRN: a context-aware post-processing framework for gene regulatory network inference revealing regulatory signatures in HIV-Leishmaniasis.BMC genomics · 2026Article
- Tegumentary Leishmaniasis Associated With Immune Reconstitution in an HIV Patient-A Case Report.Parasite immunology · 2026Article
- Article
- Atypical Manifestations of Old World Cutaneous Leishmaniasis: A Systematic Review and Clinical Atlas of Unusual Clinical and Specific Anatomical Presentations.Health science reports · 2025Review
- Evaluation of Chemokines MIG and IP-10 as Immunological Biomarkers of Human Visceral Leishmaniasis: A Systematic Review.Tropical medicine and infectious disease · 2024Review
- Synthesis of new 3-acetyl-1,3,4-oxadiazolines combined with pyrimidines as antileishmanial and antiviral agents.Molecular diversity · 2023Article
- Epidemiological, clinical and hematological profiles of visceral leishmaniasis among patients visiting Tefera Hailu Memorial Hospital, Northeast Ethiopia: a 4 year retrospective study.Scientific reports · 2023Article
- A case report and literature review: diagnosis and treatment of human immunodeficiency virus coinfected with visceral leishmania by metagenomic next-generation sequencing in China.Annals of translational medicine · 2022Article
- Potential therapeutic targets shared between leishmaniasis and cancer.Parasitology · 2021Review
- Fluralaner (Bravecto®) induces long-term mortality of Lutzomyia longipalpis after a blood meal in treated dogs.Parasites & vectors · 2020Article
- Leucocytes and Th-associated Cytokine Profile of HIV-Leishmaniasis Co-Infected Persons Attending Abuja Teaching Hospital, Nigeria.The Eurasian journal of medicine · 2020Article
- A Case-Control Study on the Association Between Intestinal Helminth Infections and Treatment Failure in Patients With Cutaneous Leishmaniasis.Open forum infectious diseases · 2020Article
- Miltefosine-Lopinavir Combination Therapy AgainstFrontiers in cellular and infection microbiology · 2019Article
- High frequency of subclinical Leishmania infection among HIV-infected patients living in the endemic areas of visceral leishmaniasis in Fars province, southern Iran.Parasitology research · 2018Article
- Unusual Signs and Symptoms in HIV-Positive Patients Coinfected withOpen access Macedonian journal of medical sciences · 2018Article
- Spectrum of clinicohematological profile and its correlation with average parasite density in visceral leishmaniasis.CytoJournal · 2018Article
- Visceral Leishmaniasis in a patient with rheumatoid arthritis undergoing treatment with methotrexate: Case report and review of the literature.European journal of rheumatology · 2017Article
- Indian visceral leishmaniasis with extensive lymphadenopathy - An unusual presentation: A case report with literature review.CytoJournal · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The Leishmaniases are a group of diseases transmitted to humans by the bite of a sandfly, caused by protozoan parasites of the genus Leishmania. Various Leishmania species infect humans, producing a spectrum of clinical manifestations. It is estimated that 350 million people are at risk, with a global yearly incidence of 1-1.5 million for cutaneous and 500,000 for visceral Leishmaniasis (VL). VL is a major cause of morbidity and mortality in East Africa, Brazil and the Indian subcontinent. Co-infection with human immunodeficiency virus (HIV) alters the immune response to the disease. Here we review the immune response to Leishmania in the setting of HIV co-infection. Improved understanding of the immunology involved in co-infections may help in designing prophylactic and therapeutic strategies against Leishmaniasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.